This website uses cookies
Read our Privacy policy and Terms of use for more information.
Long Form Content
Jul 31, 2024
•
8 min read
BioNTech & Regeneron's mRNA cancer combo reports positive Ph2 data, Merck & Co. takes earnings hit after surprise Gardasil sales slowdown in China, Roche kicks off injectable GLP-1 Ph2 trial, Pfizer looks back on track with recent earnings report, and GLP-1s may help combat smoking
Jul 30, 2024
7 min read
GSK and Flagship sign 10 drug development partnership, Boehringer Ingelheim pays up to $1.3B for Nerio Therapeutics, Merck gets positive Keytruda opinion from CHMP, Spear Bio spears $45M Series A, Cognition Therapeutics handed Ph2 Alzheimer's L, and Pfizer lays off 200+ employees across two sites
Jul 29, 2024
6 min read
BMS' strong earnings bump stock up 10%, Dexcom stock drops 40% after lowering 2024 sales forecast, multiple big pharmas land EU adcomm thumbs up, while Biogen, Eisai's Leqembi for Alzheimer's gets a thumbs down from the same committee, and Confo Therapeutics raises $65M for small molecule & antibody drug discovery
Jul 26, 2024
10 min read
Pfizer lands EU approval for their hemophilia B gene therapy, a bunch of big pharmas report earnings, Chevron Doctrine might be resurrected, Ipsen buys pediatric cancer ex-US rights from Day One Biopharmaceuticals, while Roche, AbbVie, and Sanofi all clear out some of their clinical assets
Jul 25, 2024
Pfizer's hemophilia A gene therapy posts positive Ph3, Novo Nordisk's Wegovy gets MHRA approval for a new indication, Gilead unveils full dataset for 100% efficacy HIV prevention shot, highway to funding with Autobahn's $100M Series C, FDA expresses doubt about AstraZeneca's lung cancer med prior to adcomm, and Novo Nordisk has their fourth fire of the year
Jul 24, 2024
Pfizer and Beigene open new facilities, Novo Nordisk buys 200 acres of land, Third Arc launches with $165M, Merck & Co. claim infant RSV win (but no data yet), and sinking generic prices might be exacerbating US drug shortages
Jul 23, 2024
9 min read
Agilent buys CDMO Biovectra, Samsung Bioepis's Soliris biosimilar lands FDA approval, Innovent Biologics China Ph3 type 2 diabetes win, CSL Vifor looks to make antitrust amends, and bluebird bio hits fertility program coverage issues
Jul 22, 2024
Eli Lilly ok'd to sell Zepbound in China, a $520M animal health antibody acquisition, Siga lands $113M US smallpox antiviral supply contract, GRO Biosciences GROws with $60.3M Series B, Artiva bests their own expectations with $167M IPO, and ICER isn't happy at all with Pfizer's ATTR heart disease med price
Jul 19, 2024
Novartis has a good (also not good) earnings day, Exscientia buys back asset from partner GT Apeiron, a 7th person seemingly cured of HIV infection, argenx showcases 2030 plans, J&J discontinues Addex Therapeutics epilepsy partnership
Jul 18, 2024
Roche's obesity pill posts positive Ph1, J&J earnings stay positive despite looming IRA, NGM nabs $122M raise after going private, Sanofi doubles Hyderabad workforce, Actuate's $50M upcoming IPO, FDA launches rare disease innovation hub, and Roche's Genentech bails on Relay Therapeutics partnership
Jul 17, 2024
Cardurion raises $260M for cardiac small molecules, CordenPharma invests nearly a billion in GLP-1 capacity expansion, Sionna gets hands on abandoned AbbVie CF asset, Vertex and Orum partner on new Casgevy conditioning regiment, ICER doesn't like Verona's COPD treatment price
Jul 16, 2024
Legend Biotech's alleged takeover bid, Artiva (2nd attempt) IPO aims for $135M raise, Vertex wants to cover Casgevy patient's fertility support services, Lexeo's gene therapy data disappoints, and GSK moves into London HQ
